Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan intervention for endpoint reduction in hypertension (LIFE) study

被引：7
|
作者：
Devereux, RB
Lyle, PA
机构：
[1] Cornell Univ, Weill Med Coll, Div Cardiol, New York, NY 10021 USA
[2] Merck Res Labs, West Point, PA 19486 USA
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2004年 / 5卷 / 11期
关键词：
albuminuria; angiotensin II; angiotensin-receptor antagonist; antihypertensive agents; diabetes mellitus; hypertension; isolated systolic hypertension; left ventricular hypertrophy; Losartan; stroke; uric acid;
D O I：
10.1517/14656566.5.11.2311
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Losartan is an orally active, selective, nonpeptide, angiotensin-II Type I-receptor antagonist, and was the first drug marketed in this class. It has been approved for the treatment of hypertension, and may be used alone or in combination with other anti hypertensive agents. Based on the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, losartan has been approved for the reduction of cardiovascular events in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. Based on the Reduction of Endpoints in NOW with the Angiotensin II Antagonist Losartan (RENAAL) study, losartan is also indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria, in patients with Type 2 diabetes. The focus of this review is the LIFE study.
引用
收藏
页码：2311 / 2320
页数：10
相关论文
共 50 条
  • [31] Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: The losartan intervention for endpoint reduction in hypertension (LIFE) Trial - Letter regarding article by Devereux et al.
    O'Rourke, MF
    Safar, ME
    CIRCULATION, 2005, 111 (22) : E377 - E377
  • [32] QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy -: The Losartan Intervention for Endpoint Reduction in Hypertension study
    Oikarinen, L
    Nieminen, MS
    Viitasalo, M
    Toivonen, L
    Jern, S
    Dahlöf, B
    Devereux, RB
    Okin, PM
    HYPERTENSION, 2004, 43 (05) : 1029 - 1034
  • [33] New-onset diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE)
    Lindholm, LH
    Ibsen, H
    Borch-Johnsen, K
    Olsen, MH
    Wachtell, K
    Dahlof, B
    Devereux, RB
    Beevers, G
    de Faire, U
    Fyhrquist, F
    Julius, S
    Kjeldsen, SE
    Kristianson, K
    Lederballe-Pedersen, O
    Nieminen, MS
    Omvik, P
    Oparil, S
    Wedel, H
    Aurup, P
    Edelman, J
    Snapinn, S
    CIRCULATION, 2002, 106 (19) : 573 - 573
  • [34] Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy -: The Losartan Intervention for Endpoint (LIFE) Reduction in Hypertension Study
    Okin, PM
    Devereux, RB
    Gerdts, E
    Snapinn, SM
    Harris, KE
    Jern, S
    Kjeldsen, SE
    Julius, S
    Edelman, JM
    Lindholm, LH
    Dahlöf, B
    CIRCULATION, 2006, 113 (12) : 1588 - 1596
  • [35] Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study
    Bang, Casper N.
    Gerdts, Eva
    Aurigemma, Gerard P.
    Boman, Kurt
    Dahlof, Bjoern
    Roman, Mary J.
    Kober, Lars
    Wachtell, Kristian
    Devereux, Richard B.
    JOURNAL OF HYPERTENSION, 2013, 31 (10) : 2060 - 2068
  • [36] The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin -: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study
    Fossum, E
    Moan, A
    Kjeldsen, SE
    Devereux, RB
    Julius, S
    Snapinn, SM
    Edelman, JM
    de Faire, U
    Fyhrquist, F
    Ibsen, H
    Kristianson, K
    Lederballe-Pedersen, O
    Lindholm, LH
    Nieminen, MS
    Omvik, P
    Oparil, S
    Wedel, H
    Dahlöf, B
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (05) : 770 - 775
  • [37] An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: Results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands
    Boersma, Cornelis
    Carides, George W.
    Atthobari, Jarir
    Voors, Adriaan A.
    Postma, Maarten J.
    CLINICAL THERAPEUTICS, 2007, 29 (05) : 963 - 971
  • [38] Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: The Losartan Intervention For End point reduction in hypertension (LIFE) study
    Olsen, Michael Hecht
    Wachtell, Kristian
    Beevers, Gareth
    Dahlof, Bjorn
    Devereux, Richard B.
    de Faire, Ulf
    Fyhrquist, Frej
    Ibsen, Hams
    Kjeldsen, Sverre E.
    Lederhalle-Pedersen, Ole
    Lindholm, Lars H.
    Narayan, Puneet
    Nieminen, Markku S.
    Omvik, Per
    Opard, Suzanne
    Wedel, Hans
    AMERICAN HEART JOURNAL, 2009, 157 (01) : 177 - 184
  • [39] Losartan/HydrochlorothiazideA Review of its Use in the Treatment of Hypertension and for Stroke Risk Reduction in Patients with Hypertension and Left Ventricular Hypertrophy
    Gillian M. Keating
    Drugs, 2009, 69 : 1239 - 1265
  • [40] Losartan/Hydrochlorothiazide A Review of its Use in the Treatment of Hypertension and for Stroke Risk Reduction in Patients with Hypertension and Left Ventricular Hypertrophy
    Keating, Gillian M.
    DRUGS, 2009, 69 (09) : 1239 - 1265
12345